CD274 and non-small cell lung carcinoma: With the success of PD-1/PDL-1 and CTLA-4 inhibitors in NSCLC, there is an increase interest in exploring other immune checkpoint regulators and understanding mechanisms of resistance to checkpoint inhibitors.